Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05 2023 - 4:05PM
Business Wire
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical
company focused on rare respiratory diseases, today announced that
its management team will present at the H.C. Wainwright 25th Annual
Global Investment Conference on September 12, 2023 at 3:30pm
ET/12:30pm PT. A live webcast of the presentation will be available
on Savara’s website at
www.savarapharma.com/investors/events-presentations/ and will be
archived for 90 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn:
www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905327635/en/
Savara Inc. IR & PR Anne Erickson
anne.erickson@savarapharma.com (512) 851-1366
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Apr 2024 to May 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From May 2023 to May 2024